Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 11, 2023 1:09pm
251 Views
Post# 35584166

A few questions, a few answers

A few questions, a few answers

Someone asked about M.M. Being discussed?
Answer yes.
There is a study underway & they are anticipating results, soon. I can't be more specific than that. As that topic was briefly discussed & answer to the interviewer asking about other opportunities.
The whole gambit of additional, very important information, would appear to be forthcoming.
That being between end Sept & some conference october.
They were extremely vague on Panc cancer PanCan trial. Other than to say they are still engaging conversations with various pharma, as part of the Pancreatic trial invite.
Enrolment numbers were mentioned, Various trial details. 
additional, waiting for readouts from other Goblet trials. 

I have listened to 99% of Onc presentations. over many years.
This one was the leaste conclusive on anything.
The only very firm thing they said was " the majority of the recent $15million share offering, was picked up by a medical interst"
that?
could be a pharma company, murtual fund, or a very wealthy Dr.?
again, lots of mysteries.
great weekend all.
Monday is Q2 update.
hopefully more answers by then.
 

 

<< Previous
Bullboard Posts
Next >>